Abstract: Disclosed are thallium-sensitive assay methods and compositions for identifying effectors of monovalent ion channels, transporters, or channel-linked receptors. Further described are methods that extend the detection window of an assay to ensure assay compatibility with basic fluorescence plate readers, fluorescence microscopes, high content screening instrumentation, and flow cytometers. The ability to conduct ion mobilization screens on additional instrumentation also enables significantly more complex data acquisition, analysis, and interpretation.

Abstract: Provided are novel rhodol-based compounds, the preparation method thereof, and use thereof in Tl+ flux assays. The fluorescent thallium ion sensor compounds have a rhodol fluorophore attached to an amino dicarboxylic acid metal binding moiety. The compounds are prepared in the “pro-dye” form, with the rhodol oxygen and the carboxylic acids of the metal binding unit masked by protecting groups. The disclosed compounds may be used as more red-shifted and less pH-sensitive variants of Thallos.

Abstract: Provided are N,N?-diacyl rhodamine compounds, which may be converted to rhodamine by porcine liver esterase (PLE) to produce a fluorescence signal. These compounds may be used, for example, as substrates in enzymatic assays or as labels in cellular imaging.

Abstract: Provided are novel rhodol-based compounds, the preparation method thereof, and use thereof in Tl+ flux assays. The disclosed compounds may be used as more red-shifted and less pH-sensitive variants of Thallos.

Abstract: Systems and methods are provided for imaging a target as for example a multiwell plate. A plurality of regions of interest are selected on the target at a system control. The selected plurality of regions of interest are simultaneously imaged to provide an image with the plurality of regions of interest selectively magnified by a microlens array (30) and the regions that are not of interest are rejected by means of a mirrored aperture array, a mask, or selective illumination of the regions of interest of the target.

Abstract: Systems and methods for imaging a target are provided. A system includes a detector and a substantially bitelecentric lens assembly positioned between the detector and the target. A first optical assembly is configured to focus light received from the substantially bitelecentric lens assembly onto the detector. The substantially bitelecentric lens assembly and the first optical assembly are configured to produce a collimated light space between the substantially bitelecentric lens assembly and the first optical assembly. A second optical assembly is positioned within the collimated light space.

Abstract: Systems and methods for imaging a target are provided. A system includes a detector and a substantially bitelecentric lens assembly positioned between the detector and the target. A first optical assembly is configured to focus light received from the substantially bitelecentric lens assembly onto the detector. The substantially bitelecentric lens assembly and the first optical assembly are configured to produce a collimated light space between the substantially bitelecentric lens assembly and the first optical assembly. A second optical assembly is positioned within the collimated light space.

Abstract: Systems and methods for imaging a target are provided. A system includes a detector and a substantially bitelecentric lens assembly positioned between the detector and the target. A first optical assembly is configured to focus light received from the substantially bitelecentric lens assembly onto the detector. The substantially bitelecentric lens assembly and the first optical assembly are configured to produce a collimated light space between the substantially bitelecentric lens assembly and the first optical assembly. A second optical assembly is positioned within the collimated light space.

Abstract: Systems and methods are provided for imaging a target as for example a multiwell plate. A plurality of regions of interest are selected on the target at a system control. The selected plurality of regions of interest are simultaneously imaged to provide an image with the plurality of regions of interest selectively magnified by a microlens array (30) and the regions that are not of interest are rejected by means of a mirrored aperture array, a mask, or selective illumination of the regions of interest of the target.

Abstract: Disclosed are fluorescent indicators and methods for detecting the activity of an ion channel or transporter in a cell. The indicators and methods may be used to measure influx or efflux of thallium through an ion channel or a transporter.

Abstract: In one aspect, the invention relates to sulfone compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.

Abstract: In one aspect, the invention relates to compounds, including phenylethynylbenzamide derivatives, cycloalkylethynylbenzamide derivatives, styrylbenzamide derivatives, 4-(3-phenyl-1,2,4-oxadiazol-5-yl)benzamide derivatives, 4-(pyridinylethynyl)benzamide derivatives, and N1-phenylterephthalamide derivatives, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Compounds useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) and use thereof.

Abstract: In one aspect, the invention relates to compounds having a general structure: wherein the variables are defined herein, which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Compounds useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) and methods of using the compounds.

Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Compounds useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) and use thereof.